12:00 AM
 | 
Jan 07, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Juxtapid lomitapide regulatory update

FDA approved Aegerion's Juxtapid lomitapide on Dec. 24, 2012, to treat patients with homozygous familial hypercholesterolemia (hoFH). The small molecule microsomal triglyceride transfer protein (MTP) inhibitor is approved as an adjunct to a low-fat diet and other lipid-lowering therapies, including LDL apheresis where available, to reduce LDL-C, total cholesterol, apolipoprotein B (APOB) and non-HDL-C in hoFH patients. Aegerion said it plans to launch Juxtapid in January at...

Read the full 334 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >